Investment Rating - The report gives a "Market Weight" rating for the pharmaceutical and biotechnology industry, indicating that the industry index is expected to perform within ±10% of the market index over the next six months [26]. Core Insights - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, declining by 0.75% from January 9 to January 22, 2026, which is approximately 0.46 percentage points lower than the CSI 300 index [11]. - Most sub-sectors within the industry recorded positive returns during the same period, with offline pharmacies and raw materials sectors leading with increases of 3.14% and 2.34%, respectively [12]. - Approximately 66% of stocks in the industry recorded positive returns, with the top performer, Baolait, seeing a weekly increase of 60.88% [13]. - The overall price-to-earnings (P/E) ratio for the SW pharmaceutical and biotechnology industry was approximately 52.01 times as of January 22, 2026, showing little change [19]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry lagged behind the CSI 300 index, with a decline of 0.75% from January 9 to January 22, 2026 [11]. - Most sub-sectors achieved positive returns, particularly offline pharmacies and raw materials, which rose by 3.14% and 2.34% respectively [12]. - About 66% of stocks in the industry had positive returns, with Baolait leading at a 60.88% increase [13]. - The industry’s P/E ratio was approximately 52.01 times, relative to the CSI 300's P/E ratio of 3.86 times [19]. 2. Industry News - Recent policy changes in Hebei Province have lifted restrictions on the quantity of drugs that hospitals can stock, allowing for more flexibility in drug procurement [24]. - The National Health Commission issued new medical treatment guidelines for trauma and burn victims to enhance emergency response capabilities [22][23]. 3. Company Announcements - Enhua Pharmaceutical announced the approval of a new drug registration certificate for a non-steroidal anti-inflammatory drug, which is expected to reduce the need for opioid pain relief post-surgery [25]. 4. Industry Outlook - The report suggests a focus on investment opportunities in the brain-computer interface sector, which is highlighted in the 14th Five-Year Plan, with ongoing policy support [26]. - Recommended stocks for attention include leading companies in medical devices, pharmaceutical retail, aesthetic medicine, and innovative drugs, among others [28].

Core Viewpoint - The market is experiencing significant differentiation as of Q4 2025, with a focus on the balance between returns, cycles, and risks rather than just the correctness of investment directions [1] Group 1: Fund Manager Insights - Fund manager Yao Zhipeng has been with Harvest Fund since 2011, focusing on growth and industry directions, and has extensive experience managing various product types [1][2] - The total scale of products managed by Yao Zhipeng is approximately 20 billion yuan, with Harvest Power Pioneer being a representative product [2] Group 2: Portfolio Composition - The top ten holdings of Harvest Power Pioneer include Ningde Times, Xinda Bio, Hunan Youneng, WuXi AppTec, O-film Tech, Zhongkuang Resources, Putailai, Nongfu Spring, Tianqi Lithium, and Xiaopeng Motors, indicating a multi-line structure [2][3] - The portfolio is built on three clear lines: 1. New energy, lithium battery, and new energy vehicle industry chain [3] 2. Pharmaceutical and innovative assets, reflecting ongoing attention to the innovative drug industry chain [3] 3. Consumer goods, with Nongfu Spring being one of the few hundred billion-level products in the food and beverage sector [4] Group 3: Market Environment Analysis - The overall market in Q4 2025 is characterized by a steady rise, with good returns in commercial aerospace, copper and aluminum commodities, chemicals, communications, and insurance, while cyclical assets have adjusted [4][5] - Yao Zhipeng expresses a cautious and neutral stance on the technology sector, highlighting the crowded nature of tech investments and the reevaluation of risks associated with AI [5][6] Group 4: Economic Outlook and Investment Strategy - The primary task for the Chinese economy in 2026 is to expand domestic demand, which will likely influence investment directions [6][7] - Long-term favored directions include new energy, new technology, new consumption, and innovative drugs, focusing on lithium batteries, embodied intelligent applications, and consumer assets that align with improving consumption [7] - Attention is also drawn to the potential for foreign capital inflow due to the appreciation of the RMB and the attractiveness of leading companies in various industries [8][9] Group 5: Portfolio Adjustment Strategy - Yao Zhipeng plans to gradually increase allocations to domestic demand and cyclical leading assets, enhancing the balance of the portfolio while dynamically adjusting based on macro and mid-level environmental changes [8][9]

Group 1 - The Hong Kong pharmaceutical sector is experiencing a strong rebound, with the Hong Kong Stock Connect Innovation Drug ETF (159570) rising nearly 2% and achieving a transaction volume exceeding 700 million yuan in a short period [1] - The ETF has seen a cumulative net inflow of over 430 million yuan in the past five days, with its latest scale surpassing 25.1 billion yuan, leading in its category [1] - The majority of the weighted stocks in the ETF's index have shown positive performance, including Kangfang Biopharma and Kelun-Botai, which both rose over 4% [3][4] Group 2 - Kangfang Biopharma announced that its new humanized anti-IL-17A monoclonal antibody, AK111, has received acceptance for a new drug application for treating active ankylosing spondylitis (AS) by the National Medical Products Administration (NMPA) [3] - This new drug is expected to provide a new treatment option for nearly 4 million AS patients in China [3] - The JPMorgan Healthcare Conference highlighted the achievements of Chinese innovative drug companies, with expectations for significant revenue growth and multiple drug approvals in the coming years [5][6] Group 3 - The domestic pharmaceutical industry is witnessing rapid technological advancements and an acceleration in globalization, with significant transactions exceeding 10 billion USD occurring [6][7] - The industry is entering a critical period of validation for innovative drug performance, with many companies expected to launch global registration studies and new product applications [6][7] - A domestic innovative drug company projected a revenue increase of 15.84% for 2025, with a substantial net profit growth of 102.65% [7]

Market Overview - The market has entered a phase of narrow fluctuations after a series of gains, with the Shanghai Composite Index experiencing mild adjustments since January 13. The overall trend remains stable, with orderly rotation among leading sectors [1] - On Thursday, sectors such as commercial aerospace and mining led the gains, while the semiconductor sector showed signs of slowing down. Over 3,500 stocks rose, indicating improved profitability, although trading volume decreased to 2.7 trillion [1] - The current market adjustment is seen as a healthy consolidation for the spring rally, with the focus on maintaining trading volume and the rotation of hot sectors as key factors for sustaining the market momentum [1] Future Outlook - The market is expected to shift from theme-driven to fundamentals-driven momentum, although technology growth will remain the main focus. The leading sectors since the spring rally have been driven by event-based themes like commercial aerospace and brain-computer interfaces, which, despite their long-term potential, lack short-term performance support [1] - As the market enters a consolidation phase, trading volume may decline, prompting a renewed focus on sectors driven by performance and fundamentals. The primary driver for the spring rally remains the increase in market risk appetite, with technology growth sectors expected to lead the way [1] Sector Highlights - In January, technology and raw materials sectors showed strong performance, with high-dividend stocks also being a focus for potential gains in the upcoming quarterly report season [2] - Key areas of interest include AI hardware, which is expected to see significant growth leading up to 2026, and the ongoing trend of robot commercialization, which will expand into various types of robots and related components [2] - The semiconductor industry is on a path toward domestic production, with attention on semiconductor equipment, wafer manufacturing, materials, and IC design [2] - The demand for new energy materials is rising due to rapid growth in domestic and overseas energy storage needs, with signs of supply shortages and price increases expected to continue through 2026 [2] - The innovative drug sector is anticipated to enter a recovery phase after nearly four years of adjustment, with positive net profit growth expected to continue into 2026 [2]

Core Viewpoint - Recent changes in the regulatory focus for IPO applications in the semiconductor sector indicate a shift towards evaluating core technological capabilities and operational stability, rather than just fundraising amounts and project plans [1] Group 1: IPO Applications - Two semiconductor companies have withdrawn their IPO applications from the Sci-Tech Innovation Board [2] - The regulatory review process is becoming increasingly stringent, with a focus on the details of the application process [1][2] Group 2: Market Dynamics - The true direction of the market is determined by the real attitude of capital, rather than external policies or news [1] - Quantitative data can reveal hidden behaviors of capital, allowing for a clearer understanding of market dynamics [1][5] Group 3: Institutional Participation - The "institutional inventory" metric reflects whether large institutional funds are actively participating in a stock's trading, indicating its long-term value [5][9] - Stocks with active institutional inventory tend to perform better, as they have been recognized by institutions prior to market hype [7][9] Group 4: Investment Logic - The reliance on subjective judgment and emotional responses in investment decisions can lead to poor outcomes; objective, quantifiable data should guide decisions instead [10] - A shift in understanding the importance of capital's attitude over external news can enhance investment strategies and decision-making [10]

Core Viewpoint - A new bull market, termed "confidence bull," has emerged since September 2024, driven by significant policy easing, abundant liquidity, and a new wave of technological revolution, marking a historic opportunity for investors [3][10]. Group 1: Characteristics of the Current Bull Market - This bull market is described as a once-in-a-decade event, comparable to previous major bull markets in 2004-2007 and 2014-2015, with the current market driven by policy relaxation, liquidity, and technological advancements [4][5]. - The Shanghai Composite Index has risen by 56.2% and the ChiNext Index by 122.2% since their respective lows in 2024, indicating substantial market growth [6]. - Trading volume has surged from a few hundred billion to over 3 trillion, and market capitalization has increased from 70 trillion to 123 trillion, creating a wealth effect exceeding 50 trillion [9]. Group 2: Three Major Drivers of the Bull Market - The bull market is supported by three main drivers: continuous policy easing, a new technological revolution, and abundant liquidity, which together create a "confidence bull" [10]. - Policy easing since September 2024 has included interest rate cuts, relaxed housing market restrictions, and significant infrastructure investments, leading to increased risk appetite and lower risk-free rates [10][11]. - The technological revolution, characterized by advancements in AI, robotics, and semiconductor industries, has led to a surge in high-risk growth stocks, driving the current market [11]. Group 3: Historical Missions of the Bull Market - The current bull market is expected to fulfill three historical missions: supporting the development of new productive forces, aiding in major power competition, and repairing residents' balance sheets [13]. - The transition to high-quality economic development necessitates capital market support for new economy sectors, which are often unable to secure financing through traditional banking systems [13]. - The bull market's prosperity is crucial for addressing the challenges posed by the decline in real estate values, which have significantly impacted household wealth and consumption [14]. Group 4: Future Prospects and Outlook - The sustainability of the bull market will depend on continued macroeconomic policy easing, including further interest rate cuts and fiscal measures to stimulate demand [16]. - The market's volatility, characterized by rapid rises and falls, necessitates effective regulation of leverage to ensure healthy development [16][17]. - A long-lasting bull market could significantly enhance wealth effects, stimulate economic activity, and promote technological innovation, creating a positive feedback loop for the economy [17].

Group 1 - The A-share market has been performing strongly in 2026, with the Shanghai Composite Index approaching 4200 points [1] - In contrast, the Hong Kong stock market has not returned to previous highs, although there was a notable increase on January 12, with the China Securities Hong Kong Stock Connect Internet Index and the Hang Seng Technology Index rising by 5.33% and 3.10% respectively [2] - The article explores whether this marks the beginning of a resurgence for the Hong Kong stock market [3] Group 2 - The investor structure is a key difference between the Hong Kong and A-share markets, with foreign investors accounting for 41% of trading in the Hong Kong market as of the end of 2020, making it more sensitive to U.S. dollar liquidity [4] - The sector composition also differs, with A-shares focusing on technology hardware, high-end manufacturing, and traditional consumption, while Hong Kong stocks are characterized by sectors such as dividends (finance, insurance), internet, innovative pharmaceuticals, and new consumption [7] Group 3 - Three reasons are identified for the weaker performance of the Hong Kong market compared to A-shares: 1. The strong sectors in the A-share market, such as commercial aerospace and AI computing, have not been the focus of the Hong Kong market [11] 2. Limited U.S. dollar liquidity and high U.S. Treasury yields have slowed foreign capital inflow into Hong Kong, despite a vibrant IPO market that raised 286 billion yuan in 2025 [13] 3. The macroeconomic environment has a more pronounced impact on Hong Kong stocks, with expectations for improvement in the real estate sector and consumer policies [14] Group 4 - Three potential catalysts for a stronger Hong Kong market are discussed: 1. The expansion of AI trading into downstream applications, supported by advancements in technology and the need for companies to monetize their investments [16] 2. The relationship between currency fluctuations and corporate profitability, with a strong renminbi historically correlating with higher returns in the Hong Kong market [21] 3. The trend of loose U.S. dollar liquidity, despite short-term market fluctuations, with expectations for two interest rate cuts by the Federal Reserve within the year [25] Group 5 - Investment strategies are suggested based on market conditions: - For aggressive strategies, focus on Hong Kong internet stocks due to their valuation advantages and the shift towards AI applications [30] - For allocation strategies, consider innovative pharmaceuticals, which are expected to see earnings realization [30] - For defensive strategies, dividend stocks are recommended as a hedge against market volatility [30]

Core Viewpoint - The 2025 Q4 public fund reports reveal a complex landscape characterized by "the strong getting stronger and the obscure emerging" [3] Group 1: Fund Performance - Over 40% of active equity products achieved positive quarterly returns, yet the overall fund profits still incurred losses exceeding 10 billion [4] - The top-performing fund, Yongying High-end Equipment Select A, reported a quarterly return of 56.42%, while some healthcare-themed funds experienced losses exceeding 23% [4] - Mini funds like Zhongou Cycle Select saw their scale surge from 0.36 billion to 15.75 billion, marking an increase of over 42 times [4] Group 2: Fund Manager Strategies - More than half of active equity funds opted to reduce stock positions, with over 10 products decreasing their positions by more than 20% [5] - The champion fund Yongying Technology Select A reduced its stock position from 94.41% to 80.34%, a decrease of over 14 percentage points [5] - Fund managers are showing caution towards AI hardware valuations, seeking relatively undervalued segments within the industry [9] Group 3: AI Bubble Debate - The debate over whether the AI sector has entered a bubble has intensified, with differing views among fund managers [10] - Some managers believe the AI industry is in the early stages of bubble formation, while others argue that valuations have returned to reasonable levels [11] - The core of the bubble debate revolves around the timing of technological advancements and the pace of commercial application [12] Group 4: Investment Opportunities - Fund managers are shifting their focus from beta to alpha, emphasizing the importance of stock selection [17] - In the innovative drug sector, opportunities are identified in the overseas expansion of the industry chain and domestic substitution of equipment [18] - The overall return levels in the equity market may decline, but significant structural excess return opportunities still exist [18]

Core Viewpoint - The pharmaceutical sector experienced a collective pullback today, with various indices showing declines, while there is still significant capital inflow into innovative drug ETFs, indicating a potential recovery in demand for CRO and CDMO services [1]. Group 1: Market Performance - The Hang Seng Hong Kong Stock Connect Innovative Drug Index fell by 1.4% [1]. - The CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index and the CSI Innovative Drug Industry Index both decreased by 1.1% [1]. - The CSI Biotechnology Theme Index dropped by 0.8%, and the CSI 300 Pharmaceutical and Health Index declined by 0.7% [1]. - Despite the overall market decline, the E Fund Innovative Drug ETF (159316) saw a net subscription of over 20 million units throughout the day [1]. Group 2: Industry Outlook - According to Zhongtai Securities, multiple factors are driving a gradual recovery in demand for CRO and CDMO services within the pharmaceutical sector [1]. - The past three years have seen a continuous clearing of supply, suggesting that the sector may experience a "Davis Double Play" with simultaneous improvements in profitability and valuation [1].

Group 1: Industry Overview - The Hong Kong stock market is experiencing a peak in annual performance forecasts for the fiscal year 2025, with over 280 companies having released their forecasts as of January 5, 2026. The non-ferrous metals industry is highlighted as a key contributor to profitability in the market [1]. Group 2: Company Performance Forecasts - Zijin Mining expects a net profit attributable to shareholders of 51 billion to 52 billion yuan for 2025, representing a year-on-year growth of approximately 59% to 62%. This growth is driven by increased production of key mineral products and rising sales prices of gold, copper, and silver [3]. - Zijin Gold International anticipates a net profit of about 1.5 billion to 1.6 billion USD for 2025, an increase of approximately 212% to 233% compared to the previous year, primarily due to higher gold production and successful acquisitions [3]. - Chifeng Jilong Gold Mining expects a net profit of 3 billion to 3.2 billion yuan for 2025, reflecting a year-on-year increase of about 70% to 81%, driven by increased gold production and a 49% rise in sales prices [3]. - Luoyang Molybdenum expects a net profit of 20 billion to 20.8 billion yuan for 2025, with a year-on-year growth of 47.8% to 53.71%, attributed to both increased product volume and effective cost control [4]. - Baidu expects a net profit of 135 million yuan for 2025, a significant increase of 303.57%, driven by successful overseas market expansion and growing domestic demand in biopharmaceuticals [4]. - Q Technology anticipates a comprehensive profit growth of approximately 400% to 450% for 2025, mainly due to the development of smart visual products outside the mobile phone sector and increased demand for high-value camera modules [4].